Pura Vida Investments LLC Has $5.59 Million Stock Position in Beta Bionics, Inc. $BBNX

Pura Vida Investments LLC grew its stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) by 11,150.0% in the third quarter, Holdings Channel reports. The firm owned 281,250 shares of the company’s stock after acquiring an additional 278,750 shares during the period. Beta Bionics accounts for approximately 36.1% of Pura Vida Investments LLC’s holdings, making the stock its largest position. Pura Vida Investments LLC’s holdings in Beta Bionics were worth $5,588,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. GPS Wealth Strategies Group LLC lifted its holdings in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after buying an additional 450 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after acquiring an additional 1,863 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Beta Bionics by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,558 shares of the company’s stock valued at $343,000 after acquiring an additional 2,205 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of Beta Bionics in the first quarter valued at approximately $29,000.

Beta Bionics Stock Down 1.6%

Beta Bionics stock opened at $11.38 on Thursday. The firm has a market cap of $505.04 million, a P/E ratio of -5.84 and a beta of 5.60. The business has a fifty day moving average of $18.35 and a two-hundred day moving average of $22.35. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. The business had revenue of $32.12 million for the quarter. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on BBNX shares. TD Cowen initiated coverage on Beta Bionics in a research note on Monday, January 26th. They issued a “hold” rating and a $17.00 price objective on the stock. Robert W. Baird lowered their target price on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. The Goldman Sachs Group restated a “buy” rating and set a $25.00 price target on shares of Beta Bionics in a research note on Thursday, January 15th. UBS Group upgraded Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average target price of $23.20.

Insider Transactions at Beta Bionics

In other news, CFO Stephen Feider sold 20,000 shares of Beta Bionics stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. The trade was a 31.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mike Mensinger sold 7,800 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.61, for a total transaction of $230,958.00. Following the sale, the insider directly owned 82,952 shares of the company’s stock, valued at $2,456,208.72. The trade was a 8.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 34,352 shares of company stock valued at $941,569 over the last quarter.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Recent operational/analyst context supports longer‑term upside — Beta Bionics beat EPS estimates in its Feb. 17 quarter and the consensus analyst view remains a “Moderate Buy” with a $23.20 average price target, providing a counterbalance to near‑term selling. MarketBeat coverage
• Neutral Sentiment: Short‑interest data published for early March shows implausible values (entries report “0 shares”/NaN and 0.0 days to cover), so there is no reliable signal from short sellers — treat reported short‑interest changes as inconclusive until corrected by exchanges or data providers.
• Negative Sentiment: A wave of small insider sell orders was disclosed in early March (including the CFO’s sale of 1,428 shares and several other executive sales at roughly $12.36 each). Multiple Form 4 filings and press coverage frame this as coordinated executive selling, which often pressures sentiment for small‑cap biotech/medical device stocks. TipRanks: Insiders Cash Out
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice seeking investors who experienced losses, increasing legal and reputational risk and likely weighing on near‑term sentiment until the matter is clarified. GlobeNewswire: Faruqi & Faruqi notice

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.